PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Hepatic PCs were also significantly lower in homozygous carriers of PNPLA3 I148M and enriched in carriers of HSD17B13 TA variant, consistent with their deleterious and protective effects on MASLD progression, respectively.45, 46